Dancann Pharma (DANCAN) Q4 2024 earnings summary

Executive summary

• Revenue grew 27.8% year-over-year to 7.76 MDKK, but fell 30% short of the 2024 target due to intensified competition and regulatory delays.

• EBITDA improved by 63.8% year-over-year to -4.66 MDKK, reflecting cost-saving measures and strategic focus on capital efficiency.

• Ongoing sale of the BP1 production facility and a 1,000:1 reverse stock split are expected to strengthen cash reserves and reduce administrative costs.

• Regulatory engagement led to a draft for a permanent medicinal cannabis scheme in Denmark, with further legislative steps anticipated in H1 2025.

Financial highlights

• Net sales for Q4 2024 were 1,350 kDKK, down from 1,611 kDKK in Q4 2023; full-year net sales reached 7,764 kDKK, up from 6,074 kDKK in 2023.

• EBITDA for Q4 2024 was -1,585 kDKK, a significant improvement from -3,666 kDKK in Q4 2023; full-year EBITDA improved to -4,662 kDKK from -12,887 kDKK.

• Operating loss (EBIT) for 2024 was -6,687 kDKK, compared to -59,287 kDKK in 2023.

• Result per share for 2024 was -0.0024 DKK, compared to -0.4396 DKK in 2023.

• Equity ratio increased to 0.90 at year-end 2024 from 0.53 in 2023.

Outlook and guidance

• 2025 revenue guidance is 10.0–12.5 MDKK, representing a 29.9%–62.3% increase over 2024; 2026 guidance is 20.0–25.0 MDKK, doubling 2025 revenue.

• 2025 EBITDA expected between -4.0 and -6.0 MDKK, reflecting margin pressure from competition; 2026 EBITDA guidance turns positive at 0.5–2.5 MDKK.

• Regulatory delays are expected to impact product approvals in 2025, but new product launches are anticipated to drive growth.